Results 41 to 50 of about 48,812 (228)

Successful Treatment of Nivolumab-Resistant Multiple In-Transit Melanomas with Ipilimumab and Topical Imiquimod

Case Reports in Oncology, 2018
Simultaneous or sequential, planned administration of ipilimumab could significantly enhance the antitumor effects of nivolumab in advanced melanoma patients.
Taku Fujimura, Yumi Kambayashi, Yota Sato, Kayo Tanita, Sadanori Furudate, Akira Tsukada, Hisayuki Tono, Akira Hashimoto, Setsuya Aiba   +8 more
doaj   +1 more source

European Medicines Agency extension of indication to include the combination immunotherapy cancer drug treatment with nivolumab (Opdivo) and ipilimumab (Yervoy) for adults with intermediate/poor-risk advanced renal cell carcinoma

ESMO Open, 2020
On the 15 November 2018, the Committee for Medicinal Products for Human Use adopted an extension to an existing indication for the use of nivolumab (Opdivo) in combination with ipilimumab (Yervoy) for the first-line treatment of adult patients with ...
Jorge Camarero, Filip Josephson, Maja Sommerfelt Grønvold, Nikolaos Zafiropoulos, Sahra Ali, Paula van Hennik, Christian Syvertsen, Bjorn Oddvar Strøm, Mats Ökvist, Brigitte Keller-Stanislawski, Elias Pean, Silvy da Rocha Dias, Franscesco Pignatti   +12 more
doaj   +1 more source

Cost-Effectiveness Analysis of Nivolumab Plus Ipilimumab for Advanced Non-Small-Cell Lung Cancer

Frontiers in Pharmacology, 2021
Objective: This study evaluated the cost-effectiveness of nivolumab plus ipilimumab vs. chemotherapy in the first-line setting for patients with advanced non-small-cell lung cancer (NSCLC) from the US payer perspective.Materials and methods: A Markov ...
Xiaomin Wan, Xiaohui Zeng, Liubao Peng, Ye Peng, Qiao Liu, Lidan Yi, Xia Luo, Qijian Deng, Qijian Deng, Chongqing Tan   +9 more
doaj   +1 more source

ROS Self‐Supply Nanoplatform Based on Fenton Catalyst for Chemodynamic and Immunotherapy: Reprogramming Cold Tumor Into Hot Tumor in Cancer Treatment

Advanced Science, EarlyView.
A multifunctional HA‐conjugated nanoplatform (HA‐PGMC) integrates CuO2, glucose oxidase, and mil‐100 to enable cascade catalytic ROS generation in tumor microenvironments. This self‐supplying ROS strategy induces immunogenic cell death, reprograms “cold” tumors into “hot” ones, and synergizes with PD‐L1 blockade, achieving potent chemodynamic ...
Man Lung Lee, Jack Chun Hin Chen, Wai Wing Cheng, Kwan Yee Lau, Hiu Yee Kwan, Ngar‐Yun Ellen Poon, Hung‐Wing Li   +6 more
wiley   +1 more source

Dose escalation phase 1 study of radiotherapy in combination with anti-cytotoxic-T-lymphocyte-associated antigen 4 monoclonal antibody ipilimumab in patients with metastatic melanoma

Journal for ImmunoTherapy of Cancer, 2020
Background A synergy between radiotherapy and anti-cytotoxic-T-lymphocyte-associated antigen 4 (anti-CTLA-4) monoclonal antibody has been demonstrated preclinically.
Caroline Robert, Christine Mateus, Christophe Massard, Roger Sun, Eric Deutsch, Lydie Cassard, Rastilav Bahleda, Severine Roy, Emilie Routier, Nathalie Chaput-Gras, Caroline Caramella, Emilie Lanoy, Alicia Larive, Yun Gan Tao, Dominique Schwob, Nathalie Ibrahim, Rita Maria Khoury Abboud, J -C Soria   +17 more
doaj   +1 more source

The Cancer Cell Metabolic Reprogramming Remodels the Tumor Microenvironment: Molecular Mechanisms and Therapeutic Strategies

Advanced Science, EarlyView.
This review elucidates how cancer cell metabolic reprogramming—across glucose, lipid, amino acid, and nucleotide pathways—remodels the tumor microenvironment to suppress anti‐tumor immunity and promote immune escape. Targeting these metabolic axes offers promising strategies to overcome immunotherapy resistance and enhance cancer treatment.
Guoqing Xiang, Zhicheng Zhou, Xue Jiang, Zhenguang Du, Yangyang Zhan, Xinli Liu   +5 more
wiley   +1 more source

Natural Product Toosendanin Suppresses the Malignant Development of Skin Melanoma by Targeting BNC2 for Degradation

Advanced Science, EarlyView.
BNC2 exhibits context‐dependent opposing functions across multiple cancer types. This study reveals BNC2 as an oncogenic driver of melanoma proliferation and metastasis through transcriptional activation of PIK3CA. The natural compound TSN simultaneously degrades BNC2 and its oncogenic partner SMAD3 via CRBN‐dependent ubiquitination.
Hui Dai, Xin Mei Zhang, Jing Cheng Zhang, Xu Ting Deng, Qiao Liu, Mustafa Hussein Ali, Fang Zhou Yin, Wu Yin   +7 more
wiley   +1 more source

Gastrointestinal adverse events with combination of checkpoint inhibitors in advanced melanoma: a systematic review

Melanoma Management, 2018
Introduction: Immunotherapies, including checkpoint inhibitors (CIs) such as cytotoxic T-lymphocyte antigen-4 (CTLA-4) and programmed death-1 (PD-1) inhibitors, are revolutionizing the treatment of advanced melanoma.
Elizabeth S Mearns, Jill A Bell, Aaron Galaznik, Stefanie M Puglielli, Allie B Cichewicz, Talia Boulanger, Ignacio Garcia-Ribas   +6 more
doaj   +1 more source

Role of Serum Vascular Endothelial Growth Factor (VEGF) as a Potential Biomarker of Response to Immune Checkpoint Inhibitor Therapy in Advanced Melanoma: Results of a Pilot Study

Frontiers in Oncology, 2020
Background: The development of biomarkers predictive of response to immune checkpoint inhibitor (ICI) therapies in advanced melanoma is an area of great interest in oncology.
Muhammad A. Khattak, Muhammad A. Khattak, Muhammad A. Khattak, Afaf Abed, Afaf Abed, Anna L. Reid, Ashleigh C. McEvoy, Michael Millward, Michael Millward, Melanie Ziman, Elin S. Gray   +10 more
doaj   +1 more source

Spatial Transcriptomics Reveals a T Cell‐Mediated Microglial Activation Axis of Immune Checkpoint Inhibition‐Related Adverse Events in the Brain

Advanced Science, EarlyView.
Immune checkpoint inhibition (ICI) reshapes the hippocampal neuroimmune niche. Spatial transcriptomic profiling and human brain histological analyses identify neuroinflammation and altered neuronal and glial programs. Notably, T cell depletion prevents ICI‐driven microglial activation, establishing the T cell–microglia crosstalk axis as a driving ...
Devyani Swami, Sanad M. El‐Khatib, Suhas Sureshchandra, Elise Nguyen, Janaki Manoja Vinnakota, Robert Zeiser, Shivashankar Othy, Munjal M. Acharya   +7 more
wiley   +1 more source